Form 4: Vigil Neuroscience Director Samantha Budd Haeberlein Awarded 5,000 Restricted Stock Units

Vigil Neuroscience, Inc. Director Samantha L. Budd Haeberlein has been granted 5,000 Restricted Stock Units (RSUs) as part of the company's 2021 Stock Option and Incentive Plan, increasing her beneficial ownership to 17,000 shares.

Summary

• Samantha L. Budd Haeberlein, a Director at Vigil Neuroscience, Inc. (VIGL), acquired 5,000 shares of Common Stock on May 22, 2025.
• These shares were issued as Restricted Stock Units (RSUs) under the Issuer's 2021 Stock Option and Incentive Plan, with a transaction price of $0.
• Each RSU represents the contingent right to receive one share of Vigil Neuroscience's Common Stock.
• Following this transaction, Ms. Budd Haeberlein's total beneficial ownership in the company stands at 17,000 shares.
• The RSUs are set to vest upon the earlier of May 22, 2026, or the date of the next annual meeting of the Issuer's stockholders.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued alignment of a director's interests with the company's long-term performance through equity ownership. There are no negative implications from the transaction itself, though RSUs are not immediate cash investments.

Positives

• The grant of Restricted Stock Units to a director aligns management and director interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a common and effective way to incentivize long-term commitment and performance from key personnel and board members.

Negatives

• The transaction itself, being an RSU grant, does not represent an immediate cash investment by the director, which some investors might prefer to see as a stronger signal of confidence.
• RSUs are subject to vesting conditions, meaning the shares are not immediately owned outright and can be forfeited if conditions are not met.

Risks

• The value of the RSU grant is contingent on the future stock price of Vigil Neuroscience, Inc.; if the stock price declines, the value of the compensation will also decrease.
• The RSUs are subject to forfeiture if the vesting conditions (continued service until May 22, 2026, or the next annual meeting) are not met.

Future Outlook

The future outlook for the granted RSUs is tied to their vesting schedule, which is expected to occur by May 22, 2026, or earlier upon the company's next annual meeting of stockholders. This indicates a future conversion of contingent rights into actual shares, subject to continued service.

Industry Context

The grant of Restricted Stock Units to a director is a standard practice in the biotechnology and pharmaceutical industries, where equity compensation is a primary tool for attracting, retaining, and incentivizing highly skilled executives and board members. This practice aligns the interests of the board with the long-term success and shareholder value creation of the company, which is particularly crucial in R&D-intensive sectors like neuroscience.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a common and widely accepted practice across the biotech and broader corporate landscape, aligning with compensation strategies seen in companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which frequently utilize equity grants to incentivize leadership.
• The vesting schedule, tied to a specific future date or the next annual meeting, is typical for such grants, ensuring continued commitment from the director.
• The 'price' of $0 for RSUs is standard, as they represent a contingent right to receive shares as compensation, rather than a purchase.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company's stock, potentially leading to more focused decision-making aimed at increasing shareholder value.
• Director (Samantha L. Budd Haeberlein): Receives equity compensation, incentivizing continued service and performance, with the potential for future capital gains based on company stock appreciation.

Next Steps

• The Restricted Stock Units are expected to vest upon the earlier of May 22, 2026, or the next annual meeting of Vigil Neuroscience's stockholders, at which point the director will receive the underlying common stock.

Key Dates

Keywords

Vigil Neuroscience, VIGL, Form 4, SEC filing, Restricted Stock Units, RSU, equity compensation, insider transaction, director compensation, stock option plan, beneficial ownership